Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,901 to 2,920 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR) | 38 of 1,255 24 of 1,273 | 1.1 points -0.1 to 2.4 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR) | 37 of 1,255 24 of 1,273 | 1.1 points -0.1 to 2.3 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 16 of 1,255 15 of 1,273 | 0.1 points -0.8 to 1.0 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 75 of 1,255 58 of 1,273 | 1.4 points -0.3 to 3.2 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Intervention - Aim 2 vs Control - Aim 2: Number of Patients Who Receive Contraception by Six Months Postpartum | 595 of 1,461 436 of 1,067 | -0.1 points -4.0 to 3.7 | 2,528 | NCT04092530 Linking Inter-professional Newborn and Contraception Care |
| Obicetrapib 10mg vs Placebo: deaths from any cause | 19 of 1,685 12 of 843 | -0.3 points -1.4 to 0.6 | 2,528 | NCT05142722 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies |
| Obicetrapib 10mg vs Placebo: serious adverse events | 211 of 1,685 117 of 843 | -1.4 points -4.3 to 1.4 | 2,528 | NCT05142722 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies |
| Absorb BVS vs XIENCE: TLF at 1-year, Non-inferiority Against the Control | 98 of 1,254 82 of 1,272 | 1.4 points -0.6 to 3.4 | 2,526 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Rehospitalization | 277 of 1,254 289 of 1,271 | -0.6 points -3.9 to 2.6 | 2,525 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Darbepoetin Alfa vs Placebo: deaths from any cause | 1,273 of 1,685 657 of 833 | -3.3 points -6.7 to 0.2 | 2,518 | NCT00858364 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy |
| Darbepoetin Alfa vs Placebo: serious adverse events | 524 of 1,685 259 of 833 | 0.0 points -3.9 to 3.8 | 2,518 | NCT00858364 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy |
| Intervention - Aim 2 vs Control - Aim 2: Number of Patients Who Receive Contraception by Two Months Postpartum | 474 of 1,497 339 of 1,021 | -1.5 points -5.3 to 2.2 | 2,518 | NCT04092530 Linking Inter-professional Newborn and Contraception Care |
| BDA MDI (PT027) 160/180 μg vs AS MDI (PT007) 180 µg: deaths from any cause | 2 of 1,257 1 of 1,259 | 0.1 points -0.3 to 0.5 | 2,516 | NCT05505734 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma |
| Absorb BVS vs XIENCE: Angina at 1-year, Non-inferiority Against the Control | 459 of 1,248 494 of 1,265 | -2.3 points -6.1 to 1.5 | 2,513 | NCT02173379 Absorb IV Randomized Controlled Trial |
| EHR-based Clinician Jumpstart vs Usual Care: Intensity of Care: ICU Admissions 30 Days | 336 of 1,255 348 of 1,257 | -0.9 points -4.4 to 2.6 | 2,512 | NCT04281784 Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1) |
| EHR-based Clinician Jumpstart vs Usual Care: deaths from any cause | 70 of 1,255 64 of 1,257 | 0.5 points -1.3 to 2.3 | 2,512 | NCT04281784 Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1) |
| EHR-based Clinician Jumpstart vs Usual Care: Intensity of Care: Hospital Readmissions 30 Days | 265 of 1,255 251 of 1,257 | 1.1 points -2.0 to 4.3 | 2,512 | NCT04281784 Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1) |
| Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: Major Adverse Kidney Events Within 14 Days (MAKE14) | 124 of 1,214 114 of 1,297 | 1.4 points -0.9 to 3.7 | 2,511 | NCT05094154 Effect of Antibiotic Choice On ReNal Outcomes (ACORN) |
| Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: deaths from any cause | 104 of 1,214 106 of 1,297 | 0.4 points -1.8 to 2.6 | 2,511 | NCT05094154 Effect of Antibiotic Choice On ReNal Outcomes (ACORN) |
| Vaccine vs Placebo: deaths from any cause | 1 of 1,253 11 of 1,251 | -0.8 points -1.5 to -0.3 | 2,504 | NCT00865566 Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men |
Code
curl "https://conductscience.org/api/comparisons/v1?page=146"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=146
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02173379-baba8cde",
"title": "Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)",
"summary": "38 of 1255 against 24 of 1273; risk difference 1.1 points, 95% interval -0.1 to 2.4; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-baba8cde",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2528,
"risk_difference": {
"value": 0.011425781555631363,
"lower": -0.0007441408843121729,
"upper": 0.024035205338199007
},
"group_1": "38 of 1,255",
"group_2": "24 of 1,273",
"difference": "1.1 points",
"interval": "-0.1 to 2.4",
"trial_title": "Absorb IV Randomized Controlled Trial"
},
{
"id": "NCT02173379-bea2e9c0",
"title": "Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)",
"summary": "37 of 1255 against 24 of 1273; risk difference 1.1 points, 95% interval -0.1 to 2.3; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-bea2e9c0",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2528,
"risk_difference": {
"value": 0.010628968806627379,
"lower": -0.0014595449360682716,
"upper": 0.023136081366613992
},
"group_1": "37 of 1,255",
"group_2": "24 of 1,273",
"difference": "1.1 points",
"interval": "-0.1 to 2.3",
"trial_title": "Absorb IV Randomized Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=147",
"request_id": "nIWAxE1DhHMsH20L"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant